Egle Therapeutics
PrivateLast Round
Grant
Mar 2, 2026
Total Funding Raised
$61.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Egle Therapeutics operates in Healthcare & Life Sciences and is based in Suresnes. Its latest recorded funding round was a Grant round in March 2025.
Egle Therapeutics is a biotechnology company that develops immunotherapies targeting regulatory T cells for the treatment of oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Egle Therapeutics Comparables
Compare Egle Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GentiBio | 84% | |
| Dualyx | 82% | |
| Quell Therapeutics | 81% |
For institutional investors. Book with your work email.
Egle Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 2, 2026 | ||||
| Grant | Mar 17, 2025 | ||||
| Series A | Oct 22, 2021 | ||||
| Convertible Debt | Jun 11, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Egle Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A |
| Fund+ | Series A |
| Candriam | Series A |
| Bioqube Ventures | Series A |
| JDRF | Series A |
| Takeda Ventures | Convertible Debt, Series A |
| Bpifrance | Grant, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
$9M raised from Horizon Europe
- Jan 7, 2026
John Celebi appointed as the new chief executive officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
Egle Tx presented data at the 35th EADV Congress in Austria on Sep 30th '26.
- attends_eventSep 15, 2026
Egle Tx presents clinical data on EGL-003 at the European Academy of Dermatology and Venereology (EADV) congress in Austria from Sep 30th to Oct 3rd '26.
For institutional investors. Book with your work email.
Egle Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Egle Therapeutics's valuation, stock price, and market status.
Is Egle Therapeutics a public or private company?
Egle Therapeutics is a private company.
What is the current stock price of Egle Therapeutics?
Egle Therapeutics is a private company, so its shares have no public market price. Caplight tracks Egle Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Egle Therapeutics worth (valuation)?
Valuation information for Egle Therapeutics is not publicly available.
Can I buy Egle Therapeutics stock?
Egle Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Egle Therapeutics's last funding round?
Egle Therapeutics's most recent funding round was Grant on March 2, 2026.
Who are the main investors in Egle Therapeutics?
Key investors in Egle Therapeutics include EQT Life Sciences, Bpifrance.
Will Egle Therapeutics IPO soon?
No public IPO plans have been announced for Egle Therapeutics.
How can I track Egle Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Egle Therapeutics's shares on secondary markets.